You are here: Industry Insights > Bayer

News List

Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing WorldPharmaNews
January 26, 2022
Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG - Leaps by Bayer - 8VC, and Humboldt Fund.
Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog WorldPharmaNews
January 11, 2022
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboration...
Recursion, Bayer Expand Strategic Fibrosis Alliance contractpharma
December 07, 2021
To leverage Recursion's inferential search capabilities based on maps of human cellular biology to accelerate work in fibrotic disease.
Bayer to acquire Vividion for $1.5bn to boost drug discovery platform pharmaceutical-technology
August 05, 2021
Bayer is set to acquire US-based biopharmaceutical company Vividion Therapeutics at a deal totalling up to $2bn to boost its drug discovery expertise and expand into new modalities.
Bayer appoints Head of Research and Early Development for Oncology europeanpharmaceuticalreview
July 28, 2021
Bayer have announced that Professor Dominik Ruettinger will be its new Head of Research and Early Development for Oncology, effective 1 October 2021.
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility prnasia
July 27, 2021
WuXi Biologics announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany.
Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry worldpharmanews
July 23, 2021
Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021.
MSD, Bayer’s heart failure med Verquvo gains EU approval pharmatimes
July 23, 2021
The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction.
Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients pharmatimes
July 15, 2021
Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the US to slow chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D).
Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes expresspharma
July 12, 2021
Bayer announced the United States (US) Food and Drug Administration (FDA) has approved KERENDIA (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page